Diabetes Outcomes: Comparison of Patient Assistance Programs to 340B Drug Pricing
| Autor: | Heather M. Pautler, Christine Kelso, Grace Benanti, Laura Challen |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Cost Control medicine.medical_treatment Primary care 030226 pharmacology & pharmacy Drug Costs 03 medical and health sciences 0302 clinical medicine Diabetes mellitus Internal medicine Diabetes Mellitus Medicine Humans Hypoglycemic Agents Insulin Retrospective Studies 030505 public health business.industry Public Health Environmental and Occupational Health Retrospective cohort study medicine.disease Cost control Physical therapy Patient assistance 0305 other medical science Drug pricing business |
| Zdroj: | Journal of health care for the poor and underserved. 27(3) |
| ISSN: | 1548-6869 |
| Popis: | Background. Patient assistance programs (PAPs) or obtaining 340B drug pricing offers a means of providing medications at low cost. The purpose of this study was to determine whether primary care patients who receive insulin from PAPs have an improved change in A1C, compared to 340B patients. Methods. This was a retrospective study of primary care patients who obtained insulin therapy through a PAP or 340B between June 1, 2012, and June 1, 2013. Results. The baseline and change in A1C for PAP patients was similar to 340B patients (10.3% vs. 9.3%) (–0.52 ±2.67 vs. –0.3 ±2.32, p=.66). Baseline and changes in SCr (1.0 vs. 0.99) (0.08 ±0.26 vs. 0.08 ±0.40, p=.93) and BMI (34.0 vs. 33.9) (0.15 ±2.29 vs. 0.10 ±2.16, p=.89) were also similar. PDC values averaged 0.74 in PAP patients, and 0.72 in 340B patients (p=.93). Conclusion. This study may serve as a platform for future research. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|